GlassScriptPhysician profile
Michael S Kennedy
NPI 1740224658
$1,113.34
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $54.29 · 2022: $16.67 · 2023: $264 · 2024: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $240.73 | 2019-2020 | |
| Biocryst US Sales Co., LLC | $196.59 | 2023-2024 | Orladeyo |
| Genzyme Corporation | $193.69 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $114.29 | 2019-2024 | Airsupra, Fasenra |
| Blueprint Medicines Corporation | $112.19 | 2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.80 | 2019 | |
| Shire North American Group INC | $68.45 | 2019 | |
| Genentech, INC. | $25.72 | 2023 | Xolair |
| Csl Behring | $22.18 | 2024 | Hizentra |
| Pharming Healthcare, INC. | $19.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.